Total Payments
$3,388
2024 Payments
$1,461
Companies
36
Transactions
163
Medicare Patients
1,753
Medicare Billing
$272,407
Payment Breakdown by Category
Food & Beverage$3,023 (89.2%)
Education$364.89 (10.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,023 | 155 | 89.2% |
| Education | $364.89 | 8 | 10.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $448.02 | 28 | $0 (2024) |
| Seagen Inc. | $394.27 | 15 | $0 (2023) |
| Genentech USA, Inc. | $266.88 | 13 | $0 (2024) |
| Celgene Corporation | $174.41 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $159.07 | 8 | $0 (2024) |
| Exelixis Inc. | $137.35 | 3 | $0 (2024) |
| ABBVIE INC. | $129.07 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $128.96 | 7 | $0 (2024) |
| Seattle Genetics, Inc. | $124.53 | 3 | $0 (2019) |
| GlaxoSmithKline, LLC. | $122.53 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,461 | 72 | PFIZER INC. ($332.75) |
| 2023 | $1,110 | 55 | Seagen Inc. ($214.89) |
| 2022 | $272.46 | 13 | Seagen Inc. ($64.81) |
| 2021 | $147.79 | 4 | Seagen Inc. ($99.95) |
| 2020 | $139.28 | 9 | Merck Sharp & Dohme Corporation ($41.96) |
| 2019 | $142.56 | 4 | Seattle Genetics, Inc. ($99.95) |
| 2018 | $65.45 | 4 | Seattle Genetics, Inc. ($24.58) |
| 2017 | $48.80 | 2 | AbbVie, Inc. ($24.91) |
All Payment Transactions
163 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 11/21/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.29 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo, Tecentriq | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: BioOncology | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: Oncology | ||||||
| 10/31/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $44.44 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Exelixis Inc. | — | Education | In-kind items and services | $99.95 | General |
| 10/24/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/21/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $30.72 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $0.43 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 405 | 915 | $333,637 | $64,956 |
| 2022 | 10 | 465 | 1,005 | $344,328 | $72,256 |
| 2021 | 10 | 444 | 1,023 | $319,240 | $75,992 |
| 2020 | 8 | 439 | 971 | $228,777 | $59,203 |
Total Patients
1,753
Total Services
3,914
Medicare Billing
$272,407
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 98 | 379 | $148,568 | $26,501 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 132 | $71,817 | $14,471 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 103 | 162 | $44,712 | $7,231 | 16.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 68 | $14,280 | $4,052 | 28.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 28 | $16,464 | $3,817 | 23.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 36 | $10,836 | $3,368 | 31.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $12,711 | $2,446 | 19.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $7,605 | $1,571 | 20.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 25 | 56 | $5,264 | $1,369 | 26.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 20 | $1,380 | $131.29 | 9.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 373 | $135,296 | $27,264 | 20.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 58 | 118 | $59,296 | $13,128 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 150 | 274 | $68,442 | $12,336 | 18.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 39 | $22,932 | $5,725 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 58 | $17,458 | $4,563 | 26.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 64 | $13,440 | $3,538 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $14,542 | $2,960 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $10,160 | $2,217 | 21.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 14 | 17 | $1,598 | $403.48 | 25.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 14 | 17 | $1,164 | $119.72 | 10.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 100 | 409 | $128,426 | $30,738 | 23.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 168 | 320 | $68,160 | $14,706 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 79 | $33,338 | $9,176 | 27.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 11 | 30 | $24,150 | $5,266 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 77 | $16,170 | $4,405 | 27.2% |
About Dr. Praveen Sivakumaran, MD
Dr. Praveen Sivakumaran, MD is a Hematology & Oncology healthcare provider based in Lawrenceville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1023226081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Praveen Sivakumaran, MD has received a total of $3,388 in payments from pharmaceutical and medical device companies, with $1,461 received in 2024. These payments were reported across 163 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($3,023).
As a Medicare-enrolled provider, Sivakumaran has provided services to 1,753 Medicare beneficiaries, totaling 3,914 services with total Medicare billing of $272,407. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Lawrenceville, GA
- Active Since 05/21/2007
- Last Updated 03/10/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023226081
Products in Payments
- ADCETRIS (Biological) $197.03
- IBRANCE (Drug) $129.85
- IMBRUVICA (Drug) $126.37
- DARZALEX (Biological) $105.21
- LIBTAYO (Biological) $99.68
- OPDUALAG (Drug) $92.68
- ELREXFIO (Drug) $90.53
- KEYTRUDA (Biological) $90.09
- Alecensa (Biological) $85.82
- OJJAARA (Drug) $77.46
- TUKYSA (Drug) $74.11
- EPKINLY (Drug) $68.89
- ENHERTU (Biological) $59.96
- Enhertu (Drug) $58.86
- BRAFTOVI (Drug) $57.53
- BOSULIF (Drug) $56.26
- INLYTA (Drug) $55.01
- PROVENGE (Drug) $52.23
- VERZENIO (Drug) $51.43
- OXBRYTA (Drug) $49.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lawrenceville
Dr. Jorge Leguizamo, M.d, M.D
Hematology & Oncology — Payments: $458,705
Hematology & Oncology $458,705
Dr. Vishal Ranpura, Md, MD
Hematology & Oncology — Payments: $32,896
Hematology & Oncology $32,896
Satvir Singh, M.d, M.D
Hematology & Oncology — Payments: $13,674
Hematology & Oncology $13,674
Dr. Kathleen Laveaux, M.d,, M.D,
Hematology & Oncology — Payments: $10,804
Hematology & Oncology $10,804
Dr. I-Wen Chang, M.d, M.D
Hematology & Oncology — Payments: $7,918
Hematology & Oncology $7,918
Dr. Christopher Hagenstad, M.d, M.D
Hematology & Oncology — Payments: $7,727
Hematology & Oncology $7,727